A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II Clinical Trial to Evaluate the Efficacy and Safety of ZKY001 Eye Drops in Patients With Corneal Epithelial Defects After TPRK
Latest Information Update: 21 Jan 2025
At a glance
- Drugs Timbetasin (Primary)
- Indications Corneal disorders; Myopia
- Focus Therapeutic Use
- Sponsors Zhaoke Guangzhou Ophthalmology Pharmaceutical
- 22 Jan 2024 New trial record